These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18833102)

  • 21. [Spastic syndrome. More mobile again after stroke].
    MMW Fortschr Med; 2001 Mar; 143(10):46. PubMed ID: 11268740
    [No Abstract]   [Full Text] [Related]  

  • 22. [Tolperisone in spasticity and muscle spasm. Tolperisone in multiple sclerosis].
    Nervenarzt; 1996 Jul; 67(7 Suppl Tolperison):1-4. PubMed ID: 9404528
    [No Abstract]   [Full Text] [Related]  

  • 23. Muscle relaxants and antispasticity agents.
    Meleger AL
    Phys Med Rehabil Clin N Am; 2006 May; 17(2):401-13. PubMed ID: 16616274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.
    Slawek J; Bogucki A; Reclawowicz D
    Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
    Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
    Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
    Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
    J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study.
    Jost WH; Hefter H; Reissig A; Kollewe K; Wissel J
    J Neurol Sci; 2014 Feb; 337(1-2):86-90. PubMed ID: 24361062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives.
    Natale M; Mirone G; Rotondo M; Moraci A
    Clin Neurol Neurosurg; 2012 May; 114(4):321-5. PubMed ID: 22104692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients.
    Plassat R; Perrouin Verbe B; Menei P; Menegalli D; Mathé JF; Richard I
    Spinal Cord; 2004 Dec; 42(12):686-93. PubMed ID: 15303111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
    Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
    Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of spasticity post stroke.
    Watkins CL; Leathley MJ; Gregson JM; Moore AP; Smith TL; Sharma AK
    Clin Rehabil; 2002 Aug; 16(5):515-22. PubMed ID: 12194622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
    Weynants L; Van Laere M
    Acta Belg Med Phys; 1990; 13(1):19-22. PubMed ID: 2336897
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial.
    Bresolin N; Zucca C; Pecori A
    Eur Rev Med Pharmacol Sci; 2009; 13(5):365-70. PubMed ID: 19961042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tizanidine for spasticity.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.
    Kaňovský P; Slawek J; Denes Z; Platz T; Comes G; Grafe S; Pulte I
    J Rehabil Med; 2011 May; 43(6):486-92. PubMed ID: 21533328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury.
    Stokic DS; Yablon SA; Hayes A
    Arch Phys Med Rehabil; 2005 Sep; 86(9):1801-6. PubMed ID: 16181946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
    Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
    Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.